{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:34:47Z","timestamp":1775054087125,"version":"3.50.1"},"reference-count":29,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"accepted":{"date-parts":[[2025,11,21]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the validity of the 3-item visual analog scale (3VAS) and 4-item VAS (4VAS) and determine the minimal clinically important difference (MCID) and minimal detectable change (MDC) for each measure using data from 3 phase III randomized clinical trials of guselkumab in psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pooled data (1405 participants) from the DISCOVER-1, DISCOVER-2, and COSMOS studies were used. 3VAS\/4VAS MCID and MDC were estimated using established formulas. Receiver-operating characteristic curve analysis was used to identify 3VAS\/4VAS thresholds for low, moderate, and high disease activity. Criterion validity was assessed by correlating 3VAS\/4VAS with other PsA measures. Mixed models evaluated the association between changes from baseline in 3VAS\/4VAS at week 8 of guselkumab treatment with the total PsA-modified Sharp-van der Heijde (SvdH) score through week 100.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      3VAS\/4VAS showed moderate-to-strong correlation with all outcome measures assessed, with coefficients ranging from 0.56\/0.62 for Health Assessment Questionnaire\u2013Disability Index to 0.92\/0.94 for patient global assessment. MCID was 0.9 for both 3VAS (range 0.7-1.3 depending on method used) and 4VAS (0.6-1.3); MDC was 3.1 and 3.0, respectively. 3VAS cutoffs for low, moderate, and high disease activity were 2.1, 3.3, and 4.8, respectively, and 2.1, 3.4, and 5.0 for 4VAS. Change in 4VAS at week 8 of guselkumab treatment significantly associated with change in SvdH score through week 100 (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These analyses support the validity of 3VAS\/4VAS as multidimensional measures of PsA disease activity. 4VAS may be preferred owing to its greater face validity and separate measurements of the 2 cardinal aspects of PsA (joint\/skin disease) and pain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2025-0695","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:05:34Z","timestamp":1764597934000},"page":"400-408","source":"Crossref","is-referenced-by-count":0,"title":["Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab"],"prefix":"10.3899","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-4165","authenticated-orcid":false,"given":"Marijn","family":"Vis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6063-3000","authenticated-orcid":false,"given":"Miriam","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4031-4067","authenticated-orcid":false,"given":"Karissa","family":"Lozenski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-8246","authenticated-orcid":false,"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1084","authenticated-orcid":false,"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9847-2996","authenticated-orcid":false,"given":"Mohamed","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9105","authenticated-orcid":false,"given":"Philip S.","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026040105300592000_53.4.400.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2026040105300592000_53.4.400.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00347-5"},{"key":"2026040105300592000_53.4.400.3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/art.40391","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis\/Outcome Measures in Rheumatology Consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026040105300592000_53.4.400.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217301"},{"key":"2026040105300592000_53.4.400.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200121"},{"key":"2026040105300592000_53.4.400.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122259"},{"key":"2026040105300592000_53.4.400.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2009.10.008"},{"key":"2026040105300592000_53.4.400.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.001"},{"key":"2026040105300592000_53.4.400.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201675"},{"key":"2026040105300592000_53.4.400.10","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-017-0221-4"},{"key":"2026040105300592000_53.4.400.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161459"},{"key":"2026040105300592000_53.4.400.12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002972"},{"key":"2026040105300592000_53.4.400.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0515"},{"key":"2026040105300592000_53.4.400.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0152"},{"key":"2026040105300592000_53.4.400.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1622"},{"key":"2026040105300592000_53.4.400.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"2026040105300592000_53.4.400.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"2026040105300592000_53.4.400.18","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002789"},{"key":"2026040105300592000_53.4.400.19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","article-title":"Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026040105300592000_53.4.400.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220991"},{"key":"2026040105300592000_53.4.400.21","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-20"},{"key":"2026040105300592000_53.4.400.22","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/acr.24046","article-title":"Composite measures of disease activity in psoriatic arthritis: comparative instrument performance based on the efficacy of guselkumab in an interventional phase II trial","volume":"72","author":"Helliwell","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2026040105300592000_53.4.400.23","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24242"},{"key":"2026040105300592000_53.4.400.24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030809"},{"key":"2026040105300592000_53.4.400.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(03)00044-1"},{"key":"2026040105300592000_53.4.400.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2026040105300592000_53.4.400.27","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"},{"key":"2026040105300592000_53.4.400.28","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06745-y"},{"key":"2026040105300592000_53.4.400.29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s40744-022-00436-x","article-title":"Experiences and treatment preferences in patients with psoriatic arthritis: a cross-sectional study in the ArthritisPower Registry","volume":"9","author":"Ogdie","year":"2022","journal-title":"Rheumatol Ther"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2025-0695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T12:30:38Z","timestamp":1775046638000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2025-0695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.3899\/jrheum.2025-0695"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2025-0695","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}